MANAGEMENT DEVELOPMENT TO POWERS OF THE PRODUCTION CAPITAL FUND OF THE BUILDING ENTERPRISE

In article are considered problems of the estimation and management development to powers of the main fund of the building enterprise. It is conducted critical analysis of the ways of the estimation to powers of the main fund, offered different author, and on this base is improved way, connected with choice leading link. The offered methods, allowing adjust the structure of the main fund of the building enterprise with provision for available beside it building technology

INNOVATIVE BREAD TECHNOLOGIES IN AN ACCELERATED METHOD WITH AND WITHOUT THE USE OF SOUCE AND YEAST

The article presents the results of a study of the possibilities of obtaining bread using accelerated technology, and the relationship between the obtained results of a study and the technological processes used to produce bread is considered. The express way of preparing dough on sourdough allows more efficient use of the main and additional raw materials in order to intensify the ripening of the dough and improve the quality of bread. Different technological processes of making bread were used and the revealed pattern between different technological processes, the addition of starters and the quality of bread was analyzed. As a result, the obtained bread products have high organoleptic and physico-chemical properties, corresponding to the prescription composition, and can be taken as the basis for the development of technical documentation for new types of enriched products

Research of biochemical gold recovery method using high-arsenic raw materials

This article contains the results of experiments to recover gold from complex mineral raw materials containing more than 15 % arsenic. Laboratory tests showed that standard cyanidation recovers only 26,4 % of gold into the solution. Additional oxidizing reagents used increase the leaching efficiency and enable to recover more than 40 % of gold during subsequent cyanidation. The efficiency has been established for replacement of cyanide with thiourea and thiosulfate solutions. 79,5 %, i.e. the maximum recovery rate, was found in the experiment with preliminary oxidation with T. Ferrooxidans, a bacterial culture, followed by leaching with a thiourea solution

Research of biochemical gold recovery method using high-arsenic raw materials

This article contains the results of experiments to recover gold from complex mineral raw materials containing more than 15 % arsenic. Laboratory tests showed that standard cyanidation recovers only 26,4 % of gold into the solution. Additional oxidizing reagents used increase the leaching efficiency and enable to recover more than 40 % of gold during subsequent cyanidation. The efficiency has been established for replacement of cyanide with thiourea and thiosulfate solutions. 79,5 %, i.e. the maximum recovery rate, was found in the experiment with preliminary oxidation with T. Ferrooxidans, a bacterial culture, followed by leaching with a thiourea solution

Replacement of the aortic valve, ascending aorta and arch in a patient with dextrocardia in the context of situs inversus totalis: a case report

The article discusses a rare case of successful replacement of the aortic valve, ascending  aorta and arch in a patient with dextrocardia  in the context  of situs inversus totalis. Situs inversus is a rare variant of normal anatomy  in which the major visceral organs are mirrored from their normal positions

Surgical treatment of cardiac echinococcosis: a case report

Echinococcosis refers is a chronic disease caused by tapeworms of the order Cyclophyllidea. Echinococcal cysts increase in size slowly and are often asymptomatic, and the symptoms of cardiac echinococcosis are nonspecific, which in turn can make diagnosis difficult. Early diagnosis and surgical treatment of this disease is crucial to prevent severe complications. Considering that the heart is affected extremely rarely, we want to demonstrate the successful surgical treatment

Modified Ross operation (literature review)

One of the surgical methods for treating aortic valve pathology is the Ross operation, which was proposed by the British cardiac surgeon D. Ross in 1967. Numerous studies have shown excellent long-term outcomes of this operation. However, in some patients, pulmonary autograft dilatation may occur in the long term. To avoid this complication, technical modifications of this procedure have been proposed. A literature review on modified Ross operation as a prevention of pulmonary autograft dilatation is presented

Использование сорбента на основе сверхсшитого стирол-дивинилбензольного сополимера с иммобилизованным ЛПС-селективным лигандом при гемоперфузии для лечения пациентов с септическим шоком

Aim of the study: to evaluate safety and feasibility of clinical use of an extracorporeal blood adsorber based on a hypercrosslinked styrene-divinylbenzene copolymer with immobilized lipopolysaccharide (LPS)-selective ligand designed to remove endotoxins from the bloodstream to treat patients with septic shock.Materials and methods. Nine patients (mean age 58 years, 5 men and 4 women, initial median APACHE II score 28 points, SOFA score 10 points) with confirmed Gram-negative bacterial infection and septic shock (SEPSIS-3, 2016) underwent LPS-selective hemoperfusion using an extracorporeal blood adsorber based on a hypercrosslinked styrene divinylbenzene copolymer with immobilized LPS-selective ligand for 6 hours, followed by prolonged veno-venous hemodiafiltration. Before the hemoperfusion (day 0), immediately after it, a day after its end (day 1) and once daily for the next 4 days we assessed the hemodynamic parameters, oxygenation, organ failure signs, white blood cell count, procalcitonin, C-reactive protein, clinical chemistry parameters.Results. Hemoperfusion resulted in a rapid decrease in the endotoxin activity (EAA test), more than twofold decrease in plasma level of interleukin-1 (immunoenzyme test). At the end of the procedure, the plasma lactate level decreased to normal values by day 3, pH values restored to normal within 1-2 days. The noradrenaline requirement rapidly decreased and completely resolved within 1-3 days, which corresponded to the restoration of mean blood pressure values. The values of the PaO2/FiO2 oxygenation index increased significantly after 24 hours, and the median values of 300 were maintained during all subsequent days of observation. During the first day, hemoperfudion caused a rapid decline in APACHE II and SOFA scores, while acute renal failure (estimated by urea and creatinine levels) resolved gradually by day 5. The hemoperfusion did not affect the unchanged coagulation parameters (prothrombin, fibrinogen, INR). During the first day after the procedure, we observed a short-term 1.5-fold decrease in platelet count with subsequent recovery by days 2-3 in most patients. Two patients, both differing from the rest of the patients prior to treatment in the highest values of APACHE II score (above 30), APTT (above 40) and endotoxin activity in EAA test (above 0.9), died on the 4th and 8th days of treatment. The rest of the patients survived, with clinical improvement in all parameters.Conclusion. The results of extracorporeal blood purification using Efferon LPS extracorporeal blood adsorber indicate a high therapeutic potential of the method and suggest the need for extended clinical trials to assess its clinical efficacy in ICU to reduce the high mortality in patients with septic shock.Цель исследования: оценка безопасности и определение возможности применения гемосорбента на основе сверхсшитого стирол-дивинилбензольного сополимера с иммобилизованным липополисахарид (ЛПС)-селективным лигандом, предназначенного для удаления из кровотока эндотоксинов, для лечения пациентов с септическим шоком.Материалы и методы. Девяти пациентам (средний возраст 58 лет, 5 мужчин и 4 женщины, начальные значения медиан для APACHE II 28 баллов, для SOFA 10 баллов) с подтвержденной грам-не-гативной бактериальной инфекцией и септическим шоком (СЕПСИС-3, 2016) проводили ЛПС-селек-тивную гемоперфузию (ЛСГ) с помощью колонки с сорбентом на основе сверхсшитого стирол-дивинилбензольного сополимера с иммобилизованным ЛПС-селективным лигандом в течении 6 часов с последующей продленной вено-венозной гемодиафильтрацией. До ЛСГ (день 0), сразу после нее, через сутки после ее окончания (день 1) и ежедневно на протяжении последующих 4-x суток определяли показатели гемодинамики, оксигенации, органной недостаточности, содержание лейкоцитов, прокальцитонина, С-реактивного белка, биохимические показатели.Результаты. Проведение ЛСГ приводило к быстрому снижению активности эндотоксина (ЕАА тест), более чем двукратному уменьшению содержания интерлейкина-1 (иммуноферментный тест) в плазме крови. По окончании процедуры снижалась концентрация лактата в плазме крови, доходя до нормальных значений на 3-е сутки, восстанавливались до нормальных значения рН на 1-2-е сутки. Потребность в норадреналине быстро снижалась и полностью прекращалась на 1-3-е сутки, что соответствовало восстановлению значений среднего артериального давления. Значения индекса оксигенации PaO2/FiO2 значимо повышались через сутки, значения медианы 300 удерживались на протяжении всех последующих дней наблюдения. Проведение ЛСГ обеспечивало быстрое, в течение первых суток, снижение показателей по шкалам APACHEII и SOFA, в то время как показатели острой почечной недостаточности (содержание мочевины и креатинина) градуально снижались вплоть до нормальных значений к 5- му дню. Проведение ЛСГ не приводило к изменению ненарушенных показателей системы свертывания (протромбина, фибриногена, МНО). В течение первых суток после процедуры наблюдали кратковременное 1,5-кратное снижение содержания тромбоцитов с последующим восстановлением на 2-3-и сутки у большинства пациентов. Двое пациентов, отличающихся до лечения от остальных пациентов наиболее высокими значениями оценки по шкале APACHEII (выше 30), по показателям АЧТВ (свыше 40) и значениям акивности эндотоксина в тесте ЕАА (свыше 0,9), погибли на 4-й и 8-й дни лечения. Остальные пациенты живы, с клиническим улучшением по всем показателям.Заключение. Результаты проведения экстракорпорального очищения крови с помощью колонки с сорбентом на основе сверхсшитого стирол-дивинилбензольного сополимера с иммобилизованным ЛПС-селективным лигандом указывают на высокий терапевтический потенциал примененного метода и обосновывают необходимость проведения расширенных клинических исследований с целью оценки эффективности его использования в клинической практике ОРИТ для снижения высокой летальности пациентов с септическим шоком

Синтетический аналог лей-энкефалина при COVID-19 (проспективное клиническое исследование)

One of the main problems facing intensivists when treating patients with COVID-19 is severe and critical acute respiratory distress syndrome (ARDS) with the underlying viral pneumonia. The current guidelines of the Russian Ministry of Health (Version 15 of 22.02.22) do not include drugs with a lung protective effect. This issue could be solved by administration of a synthetic analogue of leu-enkephalin.Aim. Study the efficacy of a synthetic analogue of leu-enkephalin in ARDS in patients with COVID-19.Materials and methods. The study included 35 patients divided into 2 groups. Group 1 (main) patients (n=15) in addition to standard therapy received a continuous infusion of synthetic analogue of leu-enkephalin at a rate of 5 µg/kg/hour for 5 days. Patients from group 2 (control, n=20) were treated according to the Temporary Guidelines of the Ministry of Health (V.15), but without the synthetic analogue of leu-enkephalin. The radiological data, frequency, severity and evolution of respiratory complications, changes in P/F (PaO2/FiO2) ratio, as well as changes in the scores of prognostic APACHE II, SOFA, and NEWS scales were evaluated.Results. In patients taking the studied drug, the percentage of lung damage did not change with the median (IQR) of 0 [–8; 0], while in the control group it increased by approximately 10% with the median (IQR) of +10,0 [+2; +20] (P=0.001). The proportion of patients in group 1 with positive disease evolution within 5–9 days after treatment initiation was significantly higher and reached 46.7 [24.8; 69.9]%, whereas in group 2 it was 15.0 [5.2; 36.0]% (P=0.04). Also, in group 1, starting from day 4, the median P/F ratio was significantly higher than in group 2 reaching 220 [185;245] versus 127 [111;158], respectively (P=0.014). The need for non-invasive lung ventilation in group 1 on day 7 averaged 7%, while in group 2 it was as high as 45.0%, which was significantly higher than in the main group (P=0.013).Conclusions. The use of synthetic analogue of leu-enkephalin according to the specified regimen had a significant impact on the main parameters of the viral pneumonia severity. The results serve as a rationale for the development of a novel effective treatment strategy to supplement the current standard COVID-19 management.В действующие рекомендации МЗ (№15 от 22.02.22) не включены препараты с пульмонопротекторным эффектом. Вместе с тем, одна из основных проблем, с которой сталкивается врач отделения интенсивной терапии при лечении пациентов с COVID-19 — развитие тяжелого и крайне тяжелого ОРДС на фоне вирусной пневмонии. Синтетический аналог лей-энкефалина потенциально эффективен в решении данной проблемы.Цель исследования: изучить эффективность синтетического аналога лей-энкефалина при ОРДС у пациентов с COVID-19.Материалы и методы. В проспективное исследование включили 35 пациентов, разделенных на 2 группы. Группа 1 (основная, n=15) — терапию согласно 15-м временным рекомендациям МЗ дополнили продленной инфузией синтетического аналога лей-энкефалина со скоростью 5 мкг/кг/час в течении 5 дней. Группа II (контрольная, n=20) — проводили только стандартное лечение. Оценивали данные лучевой диагностики, частоту, тяжесть и динамику респираторных осложнений, изменения показателей P/F, прогностических шкал APACHE II, SOFA и NEWS.Результаты. У пациентов, получавших исследуемый препарат, процент повреждения ткани легких не изменился: Median (IQR) 0 [–8; 0], а в контрольной группе — увеличился в среднем на 10%: Median (IQR) +10,0 [+2; +20] (p=0,001). Доля пациентов в I группе с положительной динамикой в интервале сроков с 5-го по 9-й день была значимо выше и составила 46,7% [24,8%; 69,9%], в группе II — 15,0% [5,2%; 36,0%] (p=0,04). Также в группе I, начиная с 4-х суток, медиана индекса P/F была значимо выше, чем в группе II — 220 [185; 245] против 127 [111; 158], соответственно (p=0,014). Необходимость проведения НИВЛ в группе I к 7 суткам составила в среднем 6,7%, а в группе II — 45,0%, что было значимо выше по отношению к основной группе (p=0,013).Заключение. Применение синтетического аналога лей-энкефалина оказало значимое влияние на основные показатели тяжести течения вирусной пневмонии при COVID-19, что может служить обоснованием разработки новой эффективной стратегии лечения

Pulmonary homograft dysfunction after Ross procedure in adults: a single center experience

The Ross procedure was first proposed by Donald Ross in 1967. Numerous studies show excellent long-term outcomes of the Ross operation. One of its disadvantages is the intervention on two valves due to pulmonary homograft dysfunction.Aim.  To study long-term outcomes of pulmonary homograft use after Ross operation (cumulative incidence of pulmonary homograft dysfunction, freedom from reoperation on pulmonary homograft, long-term survival, predictors of pulmonary homograft dysfunction) using data from one Russian center.Material  and  methods. A retrospective study included patients aged 18 years and older with aortic valve disease who underwent Ross procedure from April 2009 to December 2020 by a single surgeon. The age of the patients was 35 (26-44) years (men, 159 (75%)). Infective endocarditis as a cause of aortic valve pathology was diagnosed in 55 (26%) patients. Bicuspid aortic valve was diagnosed in 131 (62%) patients. The median follow-up period was 79 (26,5102,7) months.Results. Combined interventions were performed in 40 cases (18,9%). The modified Ross procedure was used in 54 (25,5%) cases (intra-aortic — 29, using Dacron tube graft — 25). Inhospital mortality was 0,5%. The 5- and 10-year allcause survival rates were 98,5% and 95,4%, while the 10-year cumulative pulmonary valve reoperation rate and pulmonary homograft dysfunction was 4,6% and 35,2%, respectively. The only factor affecting pulmonary homograft dysfunction was patient age ≤30 years (odds ratio =0,2 with 95% confidence interval: 0,06-0,7; p=0,02).Conclusion. Fresh pulmonary homografts have a low incidence of dysfunction and reintervention after Ross procedure. Young age is the only independent risk factor for pulmonary homograft dysfunction